Navigation Links
Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Date:11/7/2012

BLUE BELL, Pa., Nov. 7, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended September 30, 2012.

Total revenue was $855,000 and $3.0 million for the three and nine months ended September 30, 2012, compared to $2.6 million and $8.2 million for the same periods in 2011.

Total operating expenses were $7.1 million and $20.3 million for the three and nine months ended September 30, 2012, compared to $9.0 million and $24.0 million for the same periods in 2011.

The net loss attributable to common stockholders for the three and nine months ended September 30, 2012, was $6.6 million, or $0.05 per share, and $19.0 million, or $0.14 per share, compared to a net loss of $4.5 million, or $0.04 per share, and $9.8 million, or $0.08 per share, for the three and nine months ended September 30, 2011.

Revenue The decrease in revenue for the comparable periods was primarily due to timing of work performed under the company's contract with the National Institute of Allergy and Infectious Diseases (NIAID). This contract revenue amounted to $453,000 and $2.2 million for the three and nine months ended September 30, 2012, versus $1.9 million and $6.4 million for the same periods in 2011. This NIAID contract, which exceeds $23 million over five years (plus two additional option years), is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses Research and development expenses for the three and nine months ended September 30, 2012, were $5.0 million and $13.5 million for the three and nine months ended September 30, 2012, compared to $7.0 million and $15.9 million for the same periods in 2011. General and administrative expenses for the three and nine months ended September 30, 2012, were $2.7 million and $7.9 million versus $2.3 mil
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... Germany , Aug. 21, 2014  IBM (NYSE: ... Elektronen-Synchrotron ( DESY ), a leading national research center ... management and storage of massive volumes of x-ray data. ... based on IBM software defined technology can handle more ... performance and help scientists worldwide gain faster insights into ...
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... SAN DIEGO, June 16, 2011 Neurocrine Biosciences, Inc. ... elagolix presentations have been accepted for the scientific program ... September 4-7, 2011 in Montpellier, France. This important meeting ... every three years, bringing together clinicians and basic scientists ...
... 2011 Cebix Incorporated announced today it ... for the treatment of complications of diabetes. The biopharmaceutical ... evaluate Ersatta™, its proprietary long-acting form of C-peptide, in ... disease, lack this endogenous peptide.  Following the successful completion ...
Cached Medicine Technology:Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 2Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 2Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 4
(Date:8/22/2014)... Home Care Assistance of Centennial , North ... proud to announce the next installment in its renowned ... Dr. Suzanne Steinbaum, attending cardiologist and Director of Women’s ... City, National Spokesperson for the American Heart Association’s Go ... issues surrounding women and heart disease, what heart disease ...
(Date:8/22/2014)... -- College can be a challenging time for young people, ... to make the most of their new life, an expert ... new people and learn to manage the temptations of new ... at St. John,s University in New York City, said in ... in the classroom. College is a time when students transition ...
(Date:8/22/2014)... ItsHot.com, a client-centric manufacturer, wholesaler and ... on its range of beautiful diamond heart pendants. Customers ... Hearts 14K White Rose Gold Diamond Heart Pendant, which ... 77%. Previously priced at $3,715.00, customers can now buy ... of this mesmerizing pendant embedded with 0.66 carats round ...
(Date:8/22/2014)... According to the new research report "Isocyanate Market ... Forecast to 2019" defines and segments the isocyanate ... market value. The isocyanate material market value will ... significant CAGR from 2014 to 2019. , Browse ... through 286 pages and in-depth TOC on "Isocyanate ...
(Date:8/22/2014)... approx. 265,000 Danes are acutely admitted to medical departments ... University and Aarhus University Hospital now shows that many ... are sent home again without receiving a diagnosis ... hospitalisation., "Naturally, there is no need for a diagnosis ... is a serious illness. So some patients will always ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:College Prep 101 2Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Many patients are discharged without a diagnosis 2
... NHS hospital is, the higher the MRSA infection rate, research ... ,The impact of risk management standards on the frequency ... demanding risk management standards imposed by hospital insurers — and ... — could reduce MRSA infection rates. ,Institutions ...
... the US. Striking a blow for the pro-choice sections, New ... bill that would strengthen abortion rights. ,Only last ... Abortion Ban Act, signed by President Bush in 2003. The ... doctors say are often the safest and best to protect ...
... A team of researchers at the John Hopkins Hospital in the ... to the PSA to detect prostate cancer.// ,The new ... in a simple blood test. ,Prostate cancer, the ... areas of medicine. Physicians are unsure how to find it and ...
... little to maintaining one's health after all. A new UK study ... philosophically muse about flesh being heir to a thousand natural shocks, ... ,But the UK researchers point to a striking discrimination in the ... ages a person eight years earlier than high earners. ...
... food. That is a far more sensible way of fighting the ... , In fact prescription drugs to prevent diabetes cannot be ... ,Trials show rosiglitazone pills do work, but so does weight ... 2 diabetes, the researchers argue. ,In the British ...
... Research has shown a way for people suffering diabetic ... as alleviating the effects of diabetic retinopathy,// which is ... ,In the initial stages, retinopathy does not portray ... to cause the blood vessels of the eye to ...
Cached Medicine News:Health News:Better Risk Management Could Cut MRSA Infection Rates 2Health News:New York Governor to Introduce Bill to Strengthen Abortion Rights 2Health News:New blood test to detect prostate cancer 2Health News:Lower the wages, the faster one ages, UK study shows 2Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: